{"nctId":"NCT03337308","briefTitle":"A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy","startDateStruct":{"date":"2017-10-23","type":"ACTUAL"},"conditions":["Hyperlipidemias"],"count":382,"armGroups":[{"label":"BA 180 mg + EZE 10 mg FDC","type":"EXPERIMENTAL","interventionNames":["Combination Product: Bempedoic Acid + Ezetimibe Fixed-Dose Combination","Drug: Placebos"]},{"label":"BA 180 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Bempedoic Acid","Drug: Placebos"]},{"label":"EZE 10 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ezetimibe","Drug: Placebos"]},{"label":"Placebos","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebos"]}],"interventions":[{"name":"Bempedoic Acid + Ezetimibe Fixed-Dose Combination","otherNames":["Bempedoic Acid + Zetia FDC","ETC-1002 + Zetia"]},{"name":"Bempedoic Acid","otherNames":["ETC-1002"]},{"name":"Ezetimibe","otherNames":["Zetia"]},{"name":"Placebos","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Require lipid-modifying therapy for primary or secondary prevention of cardiovascular disease\n* Fasting LDL-C ≥ 130 mg/dL for primary prevention or LDL-C ≥ 100 mg/dL for secondary prevention (history of HeFH and/or ASCVD)\n* Treated with maximally tolerated statin therapy at stable dose for at least 4 weeks prior to screening\n\nExclusion Criteria:\n\n* Total Fasting Triglyceride ≥ 400 mg/dL\n* Renal Dysfunction or nephrotic syndrome or history of nephritis\n* Significant cardiovascular disease or cardiovascular event within the past 3 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)","description":"Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the LDL-C values from Week -2 and predose Day 1/Week 0. Percent change from baseline in LDL-C was analyzed using analysis of covariance (ANCOVA) with treatment group and randomization stratification as a factors and baseline LDL-C as a covariate. Percent change from baseline was calculated as: (\\[LDL-C value at Week 12 minus Baseline value\\] divided by \\[Baseline Value\\]) multiplied by 100. For LDL-C, if measured LDL-C value was available, measured LDL-C was used.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.2","spread":"2.56"},{"groupId":"OG001","value":"-17.2","spread":"2.52"},{"groupId":"OG002","value":"-23.2","spread":"2.18"},{"groupId":"OG003","value":"1.8","spread":"3.49"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)","description":"Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for hsCRP. Baseline was defined as the predose Day 1/Week 0 value. Percent change from baseline in hsCRP was analyzed using a non-parametric analysis. Percent change from baseline was calculated as: (\\[hsCRP value at Week 12 minus Baseline value\\] divided by \\[Baseline Value\\]) multiplied by 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.1","spread":null},{"groupId":"OG001","value":"-31.9","spread":null},{"groupId":"OG002","value":"-8.2","spread":null},{"groupId":"OG003","value":"21.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)","description":"Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for non-HDL-C. Baseline was defined as the mean of the non-HDL-C values from Week -2 and predose Day 1/Week 0. Percent change from baseline in non-HDL-C was analyzed using ANCOVA with treatment group and randomization stratification as a factors and baseline non-HDL-C as a covariate. Percent change from baseline was calculated as: (\\[non-HDL-C value at Week 12 minus Baseline value\\] divided by \\[Baseline Value\\]) multiplied by 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.9","spread":"2.23"},{"groupId":"OG001","value":"-14.1","spread":"2.17"},{"groupId":"OG002","value":"-19.9","spread":"2.05"},{"groupId":"OG003","value":"1.8","spread":"3.28"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 12 in Total Cholesterol (TC)","description":"Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the TC values from Week -2 and predose Day 1/Week 0. Percent change from baseline in TC was analyzed using ANCOVA with treatment group and randomization stratification as a factors and baseline TC as a covariate. Percent change from baseline was calculated as: (\\[TC value at Week 12 minus Baseline value\\] divided by \\[Baseline Value\\]) multiplied by 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.4","spread":"1.90"},{"groupId":"OG001","value":"-12.1","spread":"1.83"},{"groupId":"OG002","value":"-16.0","spread":"1.59"},{"groupId":"OG003","value":"0.7","spread":"2.46"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 12 in Apolipoprotein B (Apo B)","description":"Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for apo B. Baseline was defined as the predose Day 1/Week 0 value. Percent change from baseline in apo B was analyzed using ANCOVA with treatment group and randomization stratification as a factors and baseline apo B as a covariate. Percent change from baseline was calculated as: (\\[apo B value at Week 12 minus Baseline value\\] divided by \\[Baseline Value\\]) multiplied by 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.6","spread":"2.38"},{"groupId":"OG001","value":"-11.8","spread":"2.18"},{"groupId":"OG002","value":"-15.3","spread":"1.97"},{"groupId":"OG003","value":"5.5","spread":"2.97"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 12 in High-density Lipoprotein Cholesterol (HDL-C)","description":"Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for HDL-C. Baseline was defined as the mean of the HDL-C values from Week -2 and predose Day 1/Week 0. Percent change from baseline was calculated as: (\\[HDL-C value at Week 12 minus Baseline value\\] divided by \\[Baseline Value\\]) multiplied by 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.59","spread":"12.269"},{"groupId":"OG001","value":"-5.40","spread":"14.688"},{"groupId":"OG002","value":"-2.11","spread":"11.590"},{"groupId":"OG003","value":"-0.54","spread":"12.799"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 12 in Triglycerides (TGs)","description":"Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TGs. Baseline was defined as the mean of the TGs values from Week -2 and predose Day 1/Week 0. Percent change from baseline was calculated as: (\\[TGs value at Week 12 minus Baseline value\\] divided by \\[Baseline Value\\]) multiplied by 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.90","spread":"25.633"},{"groupId":"OG001","value":"7.94","spread":"42.312"},{"groupId":"OG002","value":"-2.46","spread":"33.402"},{"groupId":"OG003","value":"5.47","spread":"31.992"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":107},"commonTop":["Urinary tract infection","Nasopharyngitis","Back pain","Arthralgia","Myalgia"]}}}